|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
13 June 2016 |
|
Main ID: |
NCT02546752 |
|
Date of registration:
|
09/09/2015 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
|
|
Scientific title:
|
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine |
|
Date of first enrolment:
|
September 2015 |
|
Target sample size:
|
1306 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT02546752 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research
|
|
Phase:
|
Phase 0
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Gregory D Zimet, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
317-274-8812 |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Parents/legal guardians of 11-17 year old children.
- Children receive their healthcare at one of the 5 CHICA clinics.
- Parents are able to read either English or Spanish.
- Children have received no more than 2 doses of HPV vaccine
Exclusion Criteria:
- Parents will be excluded if their child is outside of the designated age range of
11-17 years, if the child has completed the 3-dose HPV vaccine series, or if the
parent does not read either English or Spanish.
Age minimum:
11 Years
Age maximum:
17 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Human Papilloma Virus Infection Type 18
|
|
Cervical Cancer
|
|
Human Papilloma Virus Infection Type 6
|
|
Human Papilloma Virus Infection Type 16
|
|
Human Papilloma Virus Infection Type 11
|
|
Intervention(s)
|
|
Other: THEO
|
|
Primary Outcome(s)
|
|
Outcome Measure 1: Difference Between Average HPV Vaccine Series Initiation and Completion Rates
[Time Frame: Seven Months]
|
|
Secondary Outcome(s)
|
|
Outcome Measure 1: Relative Difference in Time of Appointment
[Time Frame: Seven Months]
|
|
Secondary ID(s)
|
|
Merck - 20
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|